<DOC>
	<DOCNO>NCT03055741</DOCNO>
	<brief_summary>The objective study evaluate efficacy safety DHP1401 patient mild-moderate Alzheimer 's disease treat donepezil</brief_summary>
	<brief_title>Study DHP1401 Patients With Mild-moderate Alzheimer 's Disease Treated With Donepezil</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>1 . ≥55 ≤85 year age 2 . Patient diagnose mild moderate Alzheimer 's disease National Institute Neurological Communicative Disorders StrokeAlzheimer 's Disease Related Disorders Association ( NINCDSADRDA ) National Institute AgingAlzheimer 's Association ( NIAAA ) 3 . Korean MiniMental State Examination ( KMMSE ) score 18 26 4 . Patient maintain donepezil without dose escalation reduction least 3 month screen ( visit 1 ) 5 . Clinical Dementia Rating ( CDR ) score 0.5 2.0 screening ( visit 1 ) 6 . Written inform consent voluntarily 7 . Patient relative/caregiver support information patient 's status 8 . Patient deem adequate participate clinical trial investigator 9 . Infertility patient his/her spouse consent contraception study period 1 . A diagnosis vascular dementia dementia cause accord criterion NINCDSADRDA 2 . Structural brain abnormality impairment 3 . Schizophrenia , depressive disorder bipolar disorder 4 . Any neurological disease except Alzheimer ' disease ( ex . Parkinson 's disease , Huntington 's disease , brain tumor , normalpressure hydrocephalus , progressive supranuclear palsy , seizure disorder , subdural hematoma , multiple sclerosis , epilepsy , delusion head injury require hospitalization ) 5 . History cancer within previous 5 year 6 . History stroke within previous 2 year 7 . Heart failure require medication interventional treatment include myocardial infarction , valvular heart disease , arrhythmia within previous 1 year 8 . Uncontrollable diabetes 9 . Uncontrollable hypertension 10 . Abnormal liver kidney function 11 . Patient significant clinical meaning affect cognitive function 12 . Patient participate clinical trial within previous 3 month plan participate clinical trial study period 13 . History abuse drug alcohol within previous 2 year 14 . Patient administrate acetylcholinesterase inhibitor except donepezil within previous 4 week 15 . Patient deem inadequate participate clinical trial investigator ( ex . illiteracy , etc . ) 16 . History hypersensitivity reaction main ingredient investigational drug 17 . Patient administrate drug except donepezil dementia treatment ( possible enroll washout 28 day )</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Alzheimer 's disease</keyword>
</DOC>